These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 3961894)

  • 1. Heparin kinetics during hemodialysis: variation in sensitivity, distribution volume, and dosage.
    Seifert R; Borchert W; Letendre P; Knutson R; Cipolle R
    Ther Drug Monit; 1986; 8(1):32-6. PubMed ID: 3961894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of heparin during hemodialysis: interpatient and intrapatient variability.
    Kandrotas RJ; Gal P; Douglas JB; Deterding J
    Pharmacotherapy; 1990; 10(5):349-55. PubMed ID: 2235671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-blood activated coagulation time for evaluation of heparin activity during hemodialysis: a comparison of administration by single-dose and by infusion.
    Wilhelmsson S; Lins LE
    Clin Nephrol; 1983 Feb; 19(2):82-6. PubMed ID: 6839556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass.
    Esposito RA; Culliford AT; Colvin SB; Thomas SJ; Lackner H; Spencer FC
    J Thorac Cardiovasc Surg; 1983 Feb; 85(2):174-85. PubMed ID: 6823136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin elimination and hemostasis in hemodialysis.
    Wilhelmsson S; Lins LE
    Clin Nephrol; 1984 Dec; 22(6):303-6. PubMed ID: 6525772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Measurement of activated whole blood coagulation as a control parameter for heparin dosage in hemodialysis].
    Kraatz G; Lopot F
    Z Urol Nephrol; 1984 Aug; 77(8):465-71. PubMed ID: 6495895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between heparin level and activated clotting time in the adult cardiac surgery population.
    Fitzgerald DJ; Patel A; Body SC; Garvin S
    Perfusion; 2009 Mar; 24(2):93-6. PubMed ID: 19654150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Heparin dosage in chronic hemodialysis (author's transl)].
    Vogel GE; Hansen W; Goldmann FL; Kopp KF
    Med Klin; 1977 Oct; 72(40):1617-23. PubMed ID: 916946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a sliding scale protocol for heparin on the ability to maintain whole blood activated partial thromboplastin times within a desired range in hemodialysis patients.
    Low CL; Bailie G; Morgan S; Eisele G
    Clin Nephrol; 1996 Feb; 45(2):120-4. PubMed ID: 8846524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Individual dosage schedule of heparin therapy in chronic hemodialysis by analytic studies of blood coagulation].
    Gläser V; Anstadt M
    Z Urol Nephrol; 1990 Mar; 83(3):133-40. PubMed ID: 2356667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival of primary arteriovenous fistula in 463 patients on chronic hemodialysis.
    Puskar D; Pasini J; Savić I; Bedalov G; Sonicki Z
    Croat Med J; 2002 Jun; 43(3):306-11. PubMed ID: 12035137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of fibrinopeptide A in the evaluation of heparin activity and fibrin formation during hemodialysis.
    Wilhelmsson S; Asaba H; Gunnarsson B; Kudryk B; Robinson D; Bergström J
    Clin Nephrol; 1981 May; 15(5):252-8. PubMed ID: 7249422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated coagulation and activated partial thromboplastin times in assessment and reversal of heparin-induced anticoagulation for cardiopulmonary bypass.
    Dauchot PJ; Berzina-Moettus L; Rabinovitch A; Ankeney JL
    Anesth Analg; 1983 Aug; 62(8):710-9. PubMed ID: 6869857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of blood loss in dialysers with DEAE-cellulose membranes does not require increased doses of heparin.
    Ward RA; Schmidt B; Gurland HJ
    Nephrol Dial Transplant; 1993; 8(10):1140-5. PubMed ID: 8272230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated clotting time tests with heparinase in the management of pediatric patients on cardiopulmonary bypass.
    Kriesmer P; Payne NR; Tessmer J; Uden DL
    ASAIO J; 1993; 39(4):942-5. PubMed ID: 8123932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin kinetics: variables related to disposition and dosage.
    Cipolle RJ; Seifert RD; Neilan BA; Zaske DE; Haus E
    Clin Pharmacol Ther; 1981 Mar; 29(3):387-93. PubMed ID: 7471609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anticoagulation in hemodialysis with a single dose of low molecular weight heparin].
    Vukusich A; Avalos C; Orellana G; Cifuentes C; Rivas J; Calderón F
    Rev Med Chil; 1995 Jun; 123(6):735-41. PubMed ID: 8525227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response of kaolin ACT to heparin: evaluation with an automated assay and higher heparin doses.
    Despotis GJ; Alsoufiev AL; Spitznagel E; Goodnough LT; Lappas DG
    Ann Thorac Surg; 1996 Mar; 61(3):795-9. PubMed ID: 8619695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Use of activated coagulation time for evaluation of the degree of heparinization and calculation of heparin pharmacokinetic parameters during hemodialysis].
    Khodas MIa; Piatnitskaia GKh; Lanskaia IM; Maksimenko VA; Savina ME
    Urol Nefrol (Mosk); 1988; (3):42-8. PubMed ID: 3218006
    [No Abstract]   [Full Text] [Related]  

  • 20. Rationale for the use of a low molecular weight heparin during hemodialysis with polysulphone membrane in uremic patients.
    Moia M; Graziani G; Tenconi PM; Martinelli I; Ponticelli C
    Ann Ital Med Int; 1997; 12(2):67-71. PubMed ID: 9284597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.